The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.
Biotherapies in large vessel vasculitis / Pazzola, G; Muratore, Francesco; Pipitone, N; Salvarani, Carlo. - In: REVUE DE MEDECINE INTERNE. - ISSN 0248-8663. - 37:4(2016), pp. 274-278. [10.1016/j.revmed.2015.08.012]
Biotherapies in large vessel vasculitis
MURATORE, Francesco;SALVARANI, CARLO
2016
Abstract
The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0248866315006347-main.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
596.79 kB
Formato
Adobe PDF
|
596.79 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
